



February 26, 2015

## BioCryst to Present at Two Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2015 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq:BCRX) today announced that [executives from BioCryst](#) are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:

- The 27th Annual ROTH Conference in Laguna Niguel, CA on Monday, March 9, 2015 at 1:00 p.m. Pacific Time
- The Barclays Global Healthcare Conference in Miami, FL on Thursday, March 12, 2015 at 10:45 a.m. Eastern Time

Links to a live audio webcast and replay of these presentations may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. BioCryst currently has several ongoing development programs: oral inhibitors of plasma kallikrein for hereditary angioedema, including [BCX4161](#), [BCX7353](#) and other second generation compounds, and [BCX4430](#), a broad spectrum viral RNA polymerase inhibitor. In December 2014, [RAPIVAB](#)<sup>TM</sup> (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, was approved by the FDA and is available to treat flu patients in the U.S. For more information, please visit the Company's website at [www.BioCryst.com](http://www.BioCryst.com).

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

CONTACT: Robert Bennett, BioCryst Pharmaceuticals, +1-919-859-7910



Source: BioCryst Pharmaceuticals

News Provided by Acquire Media